The findings of randomized clinical trials in advanced NSCLC patients with classical EGFR mutations showed the outperforming of first-generation reversible EGFR-TKIs over platinum-based doublet chemotherapy (PBC) and a much larger increase in second-generation irreversible EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.